Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology

Autoimmunity Reviews

Volumn 11, Issue 12, 2012, Pages 863-872

  Peery, Harry E ^a   Day, Gregory S ^b   Dunn, Shannon ^c   Fritzler, Marvin J ^d   Prüss, Harald ^e,f   De Souza, Claire ^g   Doja, Asif ^h   Mossman, Karen ^a   Resch, Lothar ^d   Xia, Chenjie ⁱ   Sakic, Boris ^j   Belbeck, Larry ^k   Foster, Warren G ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f HARVARD MEDICAL SCHOOL   (United States)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j MCMASTER UNIVERSITY   (Canada)

^k MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

Anti NMDA receptor; Cell based assay; Encephalitis; Neuroautoimmune disease; Psychosis; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CENTRAL STIMULANT AGENT; CLONIDINE; CORTICOSTEROID; GABAPENTIN; IMMUNOGLOBULIN; LORAZEPAM; MELATONIN; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; RITUXIMAB; TRAZODONE; UNCLASSIFIED DRUG;

AKATHISIA; ANTI N METHYL DEXTRO ASPARTATE RECEPTOR ENCEPHALITIS; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; AUTOIMMUNE SYNAPTIC PROTEIN ENCEPHALOPATHY SYNDROME; B LYMPHOCYTE; BRAIN DISEASE; CATATONIA; CLINICAL FEATURE; COMORBIDITY; DELIRIUM; DRUG MEGADOSE; DYSTONIA; ELECTROCONVULSIVE THERAPY; ENCEPHALITIS; HUMAN; IMMUNOBIOLOGY; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; LOW DRUG DOSE; MOLECULAR MIMICRY; NONHUMAN; PARKINSONISM; PLASMAPHERESIS; PROGNOSIS; QT PROLONGATION; RELAPSE; REVIEW; SEIZURE; TREATMENT OUTCOME;

ANIMALS; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; ANTIPSYCHOTIC AGENTS; AUTOANTIBODIES; EARLY DIAGNOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84866552486     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.03.001     Document Type: Review

References (139)

1. Dalmau J., Tuzun E., Wu H.Y., Masjuan J., Rossi J.E., Voloschin A., et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61:25-36.
2. Dalmau J. Limbic encephalitis and variants related to neuronal cell membrane autoantigens. Rinsho Shinkeigaku 2008, 48:871-874.
3. Florance N.R., Davis R.L., Lam C., Szperka C., Zhou L., Ahmad S., et al. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009, 66:11-18.
4. Moscato E.H., Jain A., Peng X., Hughes E.G., Dalmau J., Balice-Gordon R.J. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci 2010, 32:298-309.
5. Irani S.R., Bera K., Waters P., Zuliani L., Maxwell S., Zandi M.S., et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133:6-67.
6. Gable M.S., Gavali S., Radner A., Tilley D.H., Lee B., Dyner L., et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis 2009, 28:1421-1429.
7. Gable M.S., Sheriff H., Dalmau J., Tilley D.H., Glaser C.A. The frequency of autoimmune N-methyl-d-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012, 54:899-904.
8. Prüss H., Dalmau J., Harms L., Höltje M., Ahnert-Hilger G., Borowski K., et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010, 75:1735-1739.
9. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011, 10:63-74.
10. Lancaster E., Martinez-Hernandez E., Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011, 77:179-189.
11. Titulaer M.J., Soffietti R., Dalmau J., Gilhus N.E., Giometto B., Graus F., et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 2011, 18:19-27.
12. Sébire G. In search of lost time from "Demonic Possession" to anti-N-methyl-d-aspartate receptor encephalitis. Ann Neurol 2010, 67:141-142.
13. Florance N.R., Dalmau J. Reply to: In search of lost time from "Demonic Possession" to anti-N-methyl-d-aspartate receptor encephalitis by Guillaume Sébire (2010). Ann Neurol 2010, 67:142-143.
14. Putnam J.J. Presumed title: influenza with disorders of cerebral function. Am J Med Sci 1895, 109:254.
15. Vitaliani R., Mason W., Ances B., Zwerdling T., Jiang Z., Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005, 58:594-604.
16. Hughes E.G., Peng X., Gleichman A.J., Lai M., Zhou L., Tsou R., et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010, 30:5866-5875.
17. Drachman D.B. Myasthenia gravis. N Engl J Med 1994, 330:1797-1810.
18. Lancaster E., Lai M., Peng X., Hughes E., Constantinescu R., Raizer J., et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010, 9:67-76.
19. Bataller L., Galiano R., Garcia-Escrig M., Martinez B., Sevilla T., Blasco R., et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 2010, 74:265-267.
20. B receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011, 76:795-800.
21. Hutchinson M., Kappos L., Calabresi P.A., Confavreux C., Giovannoni G., Galetta S.L., et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009, 256:405-415. [Erratum appears in J Neurol. 2009 Jun; 256(6):1035-7].
22. Dhamija R., Renaud D.L., Pittock S.J., McKeon A., Lachance D.H., Nickels K.C., et al. Neuronal voltage-gated potassium channel complex autoimmunity in children. Pediatr Neurol 2011, 44:275-281.
23. Lancaster E., Huijbers M.G., Bar V., Boronat A., Wong A., Martinez-Hernandez E., et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011, 69:303-311.
24. Irani S.R., Alexander S., Waters P., Kleopa K.A., Pettingill P., Zuliani L., et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010, 133:2734-2748.
25. Dalmau J., Rosenfeld M.R. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008, 7:327-340.
26. Kumar V., Abbas A.K., Fausto N. Neoplasia. Robbins and Cotran's pathologic basis of disease 2005, 269-342. Chapter 7, Elsevier (Saunders), Philadelphia. 7th ed. V. Kumar, A.K. Abbas, N. Fausto (Eds.).
27. Prüss H., Voltz R., Gelderblom H., Bohner G., Munz D., Zschenderlein R., et al. Spontaneous remission of anti-Ma associated paraneoplastic mesodiencephalic and brainstem encephalitis. J Neurol 2008, 255:292-294.
28. Dalmau J., Gleichman A.J., Hughes E.G., Rossi J.E., Peng X., Lai M., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7:1091-1098.
29. Prüss H., Dalmau J., Arolt V., Wandinger K.P. Anti-NMDA-rezeptor-enzephalitis. Nervenarzt 2010, 81:396-408.
30. Day G., High S., Cot B., Tang-Wai D. Anti-NMDA-receptor encephalitis: case report and literature review of an under-recognized condition. J Gen Intern Med 2011, 1-6.
31. Luca N., Daengsuwan T., Dalmau J., Jones K., deVeber G., Kobayashi J., et al. Anti-N-methyl-d-aspartate receptor encephalitis: a newly recognized inflammatory brain disease in children. Arthritis Rheum 2011, 63:2516-2522.
32. Iizuka T., Yoshii S., Kan S., Hamada J., Dalmau J., Sakai F., et al. Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. J Neurol 2010, 257:1686-1691.
33. Barry H., Hardiman O., Healy D.G., Keogan M., Moroney J., Molnar P.P., et al. Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. Br J Psychol 2011, 199:508-509.
34. Johnson N., Henry C., Fessler A.J., Dalmau J. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 2010, 75:1480-1482.
35. Fawcett R.G. Acute psychosis associated with anti-NMDA-receptor antibodies and bilateral ovarian teratomas: a case report. J Clin Psychol 2010, 71:504.
36. Biancheri R., Pessagno A., Baglietto M.G., Irani S.R., Rossi A., Giribaldi G., et al. Anti-N-methyl-d-aspartate-receptor encephalitis in a four-year-old girl. J Pediatr 2010, 156:332-334.
37. Diagnostic and statistical manual of mental disorders DMS IV TR 2000, American Psychiatric Association. IV ed.
38. Trompeo A.C., Vidi Y., Locane M.D., Braghiroli A., Mascia L., Bosma K., Ranieri V.M. Sleep disturbances in the critically ill patients: role of delirium and sedative agents. Minerva Anestesiologica 2011, 77:604-612.
39. Consoli A., Ronen K., An-Gourfinkel I., Barbeau M., Marra D., Costedoat-Chalumeau N., et al. Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report. Child Adolesc Psychiatr Ment Health 2011, 5:15.
40. Tuzun E., Rossi J.E., Karner S.F., Centurion A.F., Dalmau J. Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. J Neuroimmunol 2007, 186:177-180.
41. Chapman M.R., Vause H.E. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry 2011, 168:245-251.
42. van Swieten J.C., Koudstaal P.J., Visser M.C., Schouten H.J. van GJ. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988, 19:604-607.
43. Florance-Ryan N., Dalmau J. Update on anti-N-methyl-d-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr 2010, 22:739-744.
44. Finke C., Kopp U.A., Prüss H., Dalmau J., Wandinger K.P., Ploner C.J. Cognitive deficits following anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 2012, 83:195-198.
45. Kayser M.S., Kohler C.G., Dalmau J. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry 2010, 167:1039-1050.
46. Gabilondo I., Saiz A., Galán L., González V., Jadraque R., Sabater L., et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology 2011, 77:996-999.
47. Spillane J.E., Hirsch N.P., Kullman D.M., Taylor C., Howard R. Recurrent auto-immune NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 2010, 81.
48. Kappos L., Traboulsee A., Constantinescu C., Eralinna J.P., Forrestal F., Jongen P., et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006, 67:944-953.
49. Rozsa C., Mikor A., Kasa K., Illes Z., Komoly S. Long-term effects of combined immunosuppressive treatment on myasthenic crisis. Eur J Neurol 2009, 16:796-800.
50. Shoenfeld Y., Tincani A., Gershwin M.E. Sex gender and autoimmunity. J Autoimmun Jan 3 2012, 38:J71-J73.
51. González D.A., Díaz B.B., Rodríguez Pérez MdC, Hernández A.G., Chico B.N.D., de León A.C. Sex hormones and autoimmunity. Immunol Lett 2010, 133:6-13.
52. Whitacre C.C. Sex differences in autoimmune disease. Nat Immunol 2001, 2:777-780.
53. Voskuhl R.R., Palaszynski K. Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neuroscientist 2001, 7:258-270.
54. Kumar M.A., Jain A., Dechant V.E., Saito T., Rafael T., Aizawa H., et al. Anti-N-methyl-d-aspartate receptor encephalitis during pregnancy. Arch Neurol 2010, 67:884-887.
55. Seaman W.E., Blackman M.A., Gindhart T.D., Roubinian J.R., Loeb J.M., Talal N. beta-Estradiol reduces natural killer cells in mice. J Immunol 1978, 121:2193-2198.
56. Roubinian J., Talal N., Siiteri P.K., Sadakian J.A. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum 1979, 22:1162-1169.
57. Holmdahl R. Estrogen exaggerates lupus but suppresses T-cell-dependent autoimmune disease. J Autoimmun 1989, 2:651-656.
58. Wilder R.L. Neuroimmunoendocrinology of the rheumatic diseases. Ann N Y Acad Sci 2002, 966:13-19.
59. Offner H., Polanczyk M. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann N Y Acad Sci 2006, 1089:343-372.
60. Grimaldi C.M., Cleary J., Dagtas A.S., Moussai D., Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002, 109:1625-1633.
61. Chaudhuri J., Alt F.W. Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat Rev Immunol 2004, 4:541-552.
62. Basu U., Franklin A., Schwer B., Cheng H.L., Chaudhuri J., Alt F.W. Regulation of activation-induced cytidine deaminase DNA deamination activity in B-cells by Ser38 phosphorylation. Biochem Soc Trans 2009, 37:3-8.
63. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
64. Gono T., Kawaguchi Y., Kaneko H., Nishimura K., Hanaoka M., Kataoka S., et al. Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology 2011, 50:1578-1585.
65. Diamond B., Huerta P.T., Mina-Osorio P., Kowal C., Volpe B.T. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol 2009, 9:449-456.
66. Diamond B. Antibodies and the brain: lessons from lupus. J Immunol 2010, 185:2637-2640.
67. Drachman D.B. How to recognize an antibody-mediated autoimmune disease: criteria. Res Publ Assoc Res Nerv Ment Dis 1990, 68:183-186.
68. Tuzun E., Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 2007, 13:261-271.
69. Wu B., Goluszko E., Huda R., Tüzün E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol 2011, [Chapter 15 unit 23].
70. Bradl M., Lassmann H. Oligodendrocytes: biology and pathology. Acta Neuropathol 2010, 119:37-53.
71. Saadoun S., Waters P., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
72. Bhat R., Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 2009, 64:123-132. [Erratum appears in Neuron. 2009 Oct 29; 64(2):292].[Erratum appears in Neuron. 2009 Nov 25;64(4):590].
73. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001, 7:1189-1193.
74. Kowal C., DeGiorgio L.A., Lee J.Y., Edgar M.A., Huerta P.T., Volpe B.T., et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 2006, 103:19854-19859.
75. Murphy K. Manipulation of the immune response. Immunobiology 2012, 669-716. Chapter 16, Garland, New York. 8th ed. K. Murphy (Ed.).
76. Basten A., Silveira P.A. B-cell tolerance: mechanisms and implications. Curr Opin Immunol 2010, 22:566-574.
77. Finn O.J. Cancer immunology. N Engl J Med 2008, 358:2704-2715.
78. Xu C.L., Liu L., Zhao W.Q., Li J.M., Wang R.J., Wang S.H., et al. Anti-N-methyl-D-aspartate receptor encephalitis with serum anti-thyroid antibodies and IgM antibodies against Epstein-Barr virus viral capsid antigen: a case report and one year follow-up. BMC Neurol 2011, 11:149.
79. Belshaw R., Pereira V., Katzourakis A., Talbot G., Pa-ìes J., Burt A., et al. Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci U S A 2004, 101:4894-4899.
80. Harris J.R. Placental endogenous retrovirus (ERV): structural, functional, and evolutionary significance. Bioessays 1998, 20:307-316.
81. Balada E., Vilardell-Tarrés M., Ordi-Ros J. Implication of human endogenous retroviruses in the development of autoimmune diseases. Int Rev Immunol 2010, 29:351-370.
82. Ruprecht K., Mayer J., Sauter M., Roemer K., Mueller-Lantzsch N. Endogenous retroviruses. Cell Mol Life Sci 2008, 65:3366-3382.
83. Johnston J.B., Silva C., Holden J., Warren K.G., Clark A.W., Power C. Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases. Ann Neurol 2001, 50:434-442.
84. Shoenfeld Y., Agmon-Levin N. 'ASIA'-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
85. Agmon-Levin N., Hughes G.R.V., Shoenfeld Y. The spectrum of ASIA: 'autoimmune (auto-inflammatory) syndrome induced by adjuvants'. Lupus 2012, 21:118-120.
86. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
87. Cheng H.L., Vuong B.Q., Basu U., Franklin A., Schwer B., Astarita J., et al. Integrity of the AID serine-38 phosphorylation site is critical for class switch recombination and somatic hypermutation in mice. Proc Natl Acad Sci U S A 2009, 106:2717-2722.
88. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009, 9:429-439.
89. Nalbandian A., Crispin J.C., Tsokos G.C. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009, 157:209-215.
90. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010, 28:445-489.
91. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007, 13:1173-1175.
92. Meinl E., Derfuss T., Krumbholz M., Pröbstel A.-K., Hohlfeld R. Humoral autoimmunity in multiple sclerosis. J Neurol Sci 2011, 306:180-182.
93. Mayosi B.M., Carapetis J.R. Acute rheumatic fever. Hurst's The heart 2008, 1691-1696. Chapter 74, McGraw-Hill, New York. 12 ed. B.M. Mayosi, J.R. Carapetis (Eds.).
94. Church A.J., Cardoso F., Dale R.C., Lees A.J., Thompson E.J., Giovannoni G. Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology 2002, 59:227-231.
95. Martino D., Defazio G., Church A.J., Dale R.C., Giovannoni G., Robertson M.M., et al. Antineuronal antibody status and phenotype analysis in Tourette's syndrome. Mov Disord 2007, 22:1424-1429.
96. Dale R.C., Candler P.M., Church A.J., Wait R., Pocock J.M., Giovannoni G. Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol 2006, 172:187-197.
97. Ortega-Hernandez O.D., Levin N.A., Altman A., Shoenfeld Y. Infectious agents in the pathogenesis of primary biliary cirrhosis. Dis Markers 2010, 29:277-286.
98. Anderson M., Suh J.M., Kim E.Y., Dryer S.E. Functional NMDA receptors with atypical properties are expressed in podocytes. Am J Physiol Cell Physiol 2011, 300:C22-C32.
99. Parisi E., Almaden Y., Ibarz M., Panizo S., Cardus A., Rodriguez M., et al. N-methyl-d-aspartate receptors are expressed in rat parathyroid gland and regulate PTH secretion. Am J Physiol Renal Physiol 2009, 296:F1291-F1296.
100. Patton A.J., Genever P.G., Birch M.A., Suva L.J., Skerry T.M. Expression of an N-methyl-d-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone. Bone 1998, 22:645-649.
101. Quesada I., Tuduri E., Ripoll C., Nadal A. Physiology of the pancreatic {alpha}-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 2008, 199:5-19.
102. Seeber S., Humeny A., Herkert M., Rau T., Eschenhagen T., Becker C.M. Formation of molecular complexes by N-methyl-d-aspartate receptor subunit NR2B and ryanodine receptor 2 in neonatal rat myocard. J Biol Chem 2004, 279:21062-21068.
103. Dickman K.G., Youssef J.G., Mathew S.M., Said S.I. Ionotropic glutamate receptors in lungs and airways: molecular basis for glutamate toxicity. Am J Respir Cell Mol Biol 2004, 30:139-144.
104. Genever P.G., Wilkinson D.J., Patton A.J., Peet N.M., Hong Y., Mathur A., et al. Expression of a functional N-methyl-d-aspartate-type glutamate receptor by bone marrow megakaryocytes. Blood 1999, 93:2876-2883.
105. Mashkina A.P., Cizkova D., Vanicky I., Boldyrev A.A. NMDA receptors are expressed in lymphocytes activated both in vitro and in vivo. Cell Mol Neurobiol 2010, 30:901-907.
106. Makhro A., Wang J., Vogel J., Boldyrev A.A., Gassmann M., Kaestner L., et al. Functional NMDA receptors in rat erythrocytes. Am J Physiol Cell Physiol 2010, 298:C1315-C1325. [Erratum appears in Am J Physiol Cell Physiol. 2010 Dec;299(6):C1571-3].
107. Coggeshall R.E., Carlton S.M. Ultrastructural analysis of NMDA, AMPA, and kainate receptors on unmyelinated and myelinated axons in the periphery. J Comp Neurol 1998, 391:78-86.
108. Shannon H.E., Sawyer B.D. Glutamate receptors of the N-methyl-d-aspartate subtype in the myenteric plexus of the guinea pig ileum. J Pharm Exp Ther 1989, 251:518-523.
109. Lachance D.H., Lennon V.A., Pittock S.J., Tracy J.A., Krecke K.N., Amrami K.K., et al. An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol 2010, 9:55-66.
110. Meeusen J.W., Klein C.J., Pirko I., Haselkorn K.E., Kryzer T.J., Pittock S.J., et al. Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol. Ann Neurol 2011.
111. Kamm C., Zettl U.K. Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev 2012, 11:196-202.
112. Conrad K., Schößler W., Hiepe F., Fritzler M.J. Organ specific autoimmune diseases: a diagnostic reference 2011, Vol. 8:115. Pabst Science Publishers, Lengerich, Germany.
113. De Baets M.H. Insights in the autoimmunity of myasthenia gravis. Autoimmunity 2010, 43:341-343.
114. Quintana F.J., Farez M.F., Weiner H.L. Translational therapies for immune-based disorders review series: systems biology approaches for the study of multiple sclerosis. J Cell Mol Med 2008, 12:1087-1093.
115. Jarius S., Paul F., Franciotta D., de Seze J., Münch C., Salvetti M., et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 2011.
116. Keegan B.M., Noseworthy J.H. Multiple sclerosis. Ann Rev Med 2002, 53:285-302.
117. Roemer S.F., Parisi J.E., Lennon V.A., Benarroch E.E., Lassmann H., Bruck W., et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194-1205.
118. Lassmann H., Br++ck W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007, 17:210-218.
119. Martinez-Hernandez E., Horvath J., Shiloh-Malawsky Y., Sangha N., Martinez-Lage M., Dalmau J. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011, 77:589-593.
120. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
121. Kim W., Kim S.H., Kim H.J. New insights into neuromyelitis optica. J Clin Neurol 2011, 7:115-127.
122. Carlsson B., Wallin J., Pirskanen R., Matell G., Smith C.I. Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics 1990, 31:285-290.
123. McElroy J.P., Oksenberg J.R. Multiple sclerosis genetics 2010. Neurol Clin 2011, 29:219-231.
124. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
125. Cavalcante P., Serafini B., Rosicarelli B., Maggi L., Barberis M., Antozzi C., et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010, 67:726-738.
126. Meyer M., Höls A.K., Liersch B., Leistner R., Gellert K., Schalke B., et al. Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus. Ann Neurol 2011, 70:515-518.
127. Kakalacheva K., Maurer M.A., Tackenberg B., Münz C., Willcox N., Lünemann J.D. Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis. Ann Neurol 2011, 70:508-514.
128. Kakalacheva K., Münz C., Lünemann J.D. Viral triggers of multiple sclerosis. Biochim Biophys Acta 2011, 1812:132-140.
129. Wingerchuk D.M., Lucchinetti C.F. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 2007, 20:343-350.
130. Beeson P.B. Age and sex associations of 40 autoimmune diseases. Am J Med 1994, 96:457-462.
131. Orton S.M., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V., Sadovnick A.D., et al. Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006, 5:932-936.
132. Cornelio D., Braga R., Rosa M., Ayub An DevicΓÇÖs neuromyelitis optica and pregnancy: distinction from multiple sclerosis is essential. Arch Gynecol Obstet 2009, 280:475-477.
133. Hoff J.M., Daltveit A.K., Gilhus N.E. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007, 14:38-43.
134. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998, 339:285-291.
135. Ducray F., Roos-Weil R., Garcia P.Y., Slesari J., Heinzlef O., Chatelain D., et al. Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2007, 78:325-327.
136. Antoine J.-C., Camdessanché J.-P., Absi L., Lassablière F., Féasson L. Devic disease and thymoma with anti-central nervous system and antithymus antibodies. Neurology 2004, 62:978-980.
137. Wingerchuk D.M. Diagnosis and treatment of neuromyelitis optica. Neurologist 2007, 13:2-11.
138. Angelini C. Diagnosis and management of autoimmune myasthenia gravis. Clin Drug Investig 2011, 31:1-14.
139. Hassan-Smith G., Douglas M.R. Management and prognosis of multiple sclerosis. Br J Hosp Med (Lond) 2011, 72:M174-M176.